Stem cell therapy market

  title={Stem cell therapy market},
  author={Basharut A. Syed and James B. Evans},
  journal={Nature Reviews Drug Discovery},
Products based on stem cells show promise in diverse therapeutic areas, including cardiovascular and autoimmune diseases. This article analyses the late-stage pipeline of stem cell therapies and provides a market overview. 
The role of biomaterials in stem cell-based regenerative medicine.
The possible advancements in translational therapy by using biomaterials with stem cells are prospected and the challenges of the current restriction in clinical applications are highlighted. Expand
Stem cells in cardiovascular diseases: turning bad days into good ones.
It is suggested that, in the short term, the major impact of PSCs in the cardiovascular field might be at the bench and not the bedside, which is far from the revolutionary improvements expected for heart function. Expand
Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
A series of technological advances in all aspects of hPSC-based therapeutic product manufacturing including clinical grade cell line development, large-scale banking, upstream processing, downstream processing, and quality assessment of final cell therapeutic products that have brought hPSCs closer to clinical application and commercial cGMP manufacturing are highlighted. Expand
Cell Therapy Landscape: Autologous and Allogeneic Approaches
In this chapter, an analysis is performed of the commercial potential of the autologous and allogeneic approaches to cell therapy, in terms of where each approach may best be positioned from a commercial perspective. Expand
The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.
Among these evolutions, based on the need for mesenchymal stem cells to be recruited by an inflammatory environment, the development and use of novel GvHD biomarkers could be explored further to deliver the right pharmaceutical to the right patient at the right time. Expand
Toward biomanufacturing of pluripotent stem cell derived products: scale out and scale up
Current and emerging technologies are being explored to fulfill the potential of scale up culture systems with the emphasis on the design of bioinspired process for large-scale biomanufacturing of stem cells. Expand
Are Clinical Trials With Mesenchymal Stem/Progenitor Cells too Far Ahead of the Science? Lessons From Experimental Hematology
The history of stem cell therapy indicates that development of a dramatically new therapy usually requires patience and a constant dialogue between basic scientists and physicians carrying out carefully designed clinical trials, and suggests that the field can be moved forward by establishing better records of how MSCs are prepared. Expand
The safety of non-expanded multipotential stromal cell therapies
This chapter will provide an overview on the current state of the art in the field of uncultured MSCs as cell therapy, and discuss highly pertinent safety issues such as purity and the role of contaminating immune and non-immune cells. Expand
Mesenchymal Stem Cells in Regenerative Medicine for Musculoskeletal Diseases: Bench, Bedside, and Industry
The status of preclinical animal studies, clinical trials, and the efforts of the industry in using MSCs to treat musculoskeletal diseases such as bone fractures, bone defects, focal chondral lesions, osteoarthritis, spinal diseases, and tendon injuries are reviewed. Expand
Nonclinical Studies for Cell-Based Medicines
This chapter aims to provide advice on the aspects to consider when designing the nonclinical programs, potential limitations and how to address these, and to introduce the concept of the risk-based approach. Expand


World Market Outlook 2012–2022
  • Visiongain
  • 2012